Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing...
Ocugen
Ocugen (NASDAQ: OCGN) reported Q1 2025 financial results and provided updates on...
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing...
Ocugen (NASDAQ: OCGN) reported Q1 2025 financial results and provided updates on...